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Expression of fibroblast growth factors and their receptors in rat
glomeruli. Fibroblast growth factors (FGFs) regulate cell proliferation
and differentiation, and are also important regulators of extracellular
matrix. They are among the most potent angiogenic factors known.
Evidence suggests the FGFs play a role in glomerular development and
pathology. The aim of the present study was to determine whether FGF-1
(acidic FGF) and FGF-2 (basic FGF) and their receptors (FGFRs) were
expressed in normal adult rat glomeruli, using reverse transcriptase-
polymerase chain reaction (RT-PCR) and immunohistochemistry. For
RT-PCR studies, the kidneys of 200 g female Sprague-Dawley rats were
perfused with buffer and glomeruli isolated using conventional sieving
techniques followed by micropipetting. FGF-1 and FGF-2 were expressed
in cortex and in glomeruli. All seven receptor isoforms assayed (FGFRI,
2 and 3 IlIb and IlIc splice variants, and FGFR4) were expressed in whole
Cortex. However, only the IlIc variants and FGFR4 were expressed in
glomeruli. The relative levels of glomerular expression of these isoforms
were determined using a semiquantitative RT-PCR assay using primers
designed against three transmembrane regions: FGFR1 (100%); FGFR2
(0.1%); and FGFR4 (6%). Immunohistochemistry revealed specific im-
munostaining for all four FGFRs within glomeruli. The differential
expression pattern of FGFR isoforms between glomeruli and whole
cortex, and the mutually exclusive nature of the expression of IlIc but not
IlIb isoforms within glomeruli, indicates that FGFR expression and
thereby FGF activity is tightly regulated in glomeruli. These findings have
important implications for the roles of the FGFs in glomerular health and
disease.
The fibroblast growth factors (FGFs) are a family of growth and
differentiation factors with a wide variety of effects. Nine members
of the FGF family have been identified: FGF-1 (acidic FGF),
FGF-2 (basic FGF), FGF-3 (int-2), FGF-4 (hst/kFGF), FGF-5,
FGF-6, FGF-7 (KGF), FGF-8 and FGF-9 [1, 2]. FGF-1 and
FGF-2 have been the most studied and are potent mitogens for a
variety of mesoderm and neuroectoderm derived cell types [3].
They also act as differentiation factors for a variety of cell types,
and regulate synthesis and turnover of the extracellular matrix.
The FGFs arc among the most potent angiogenic factors yet
discovered [4].
The biological effects of the FGFs are mediated by their
combined interactions both with specific, high affinity cell-surface
receptors (FGFRs) and low affinity receptors, heparan sulfate
proteoglycans (HSPGs), present on the cell surface and within the
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surrounding extracellular matrix. Four types of high affinity
receptors (FGFRI to -4) have been cloned [5—9]. These different
receptors show a high degree of conservation both between
themselves and between species [4, 101. Differential splicing
generates a bewildering array of variants within a single receptor
type. It is becoming increasingly apparent that different isoforms
have different affinities for the various FGF ligands [11—13]. A
splicing event that particularly influences receptor affinity for a
specific FGF involves the C-terminal half of the third Ig-like loop
(loop III) in the ectodomain of the receptor. Studies on the
genomic organization of FGFR1, FGFR2 and FGFR3 have
shown that each of these genes contain two exons, Ilib and Ilic,
which lie in close proximity to each other and can be alternatively
spliced into the C-terminal half of loop III to generate Ilib and
Ilic variants [14—17]. FGFR1 Ilic has a greater affinity for FGF-2
than FGF-1, FGFR2 Ilib will bind FGF-1 and FGF-7 with equal
affinity but will not bind FGF-2, while FGFR2 Ilic binds FGF-2
and FGF-1 equally well but will not bind FGF-7. FGFR3 Ilib is
highly specific for FGF-1. Knowledge of which FGFR isoforms
are present in a tissue has direct bearing on whether a FGF has
potential activity in that tissue.
Both FGF-1 and FGF-2 have been isolated from a number of
mammalian kidneys [18—201, although their precise cellular local-
ization remains somewhat controversial [21—29]. mRNA for both
FGF-1 and FGF-2 have been isolated from adult kidney [30, 31].
Floege et al [23] demonstrated three molecular weight isoforms of
FGF-2 in isolated rat glomeruli, but did not detect FGF-2 mRNA
by Northern analysis. The kidney also expresses antisense FGF-2
mRNA [32, 331.
Very little is known about the types and localization of the
FGFRs in the adult kidney. Hughes and Hall [22] were unable to
demonstrate immunostaining for FGFR1 in human kidney.
Floege et a! [34] reported a similar finding for rat glomeruli..
Ledoux et al [35] and Olwin and Hauschka [36] did not detect
high-affinity FGF receptors in kidney membrane preparations.
With reverse transcriptase-polymerase chain reaction (RT-PCR),
Luqmani, Graham and Coombes [37] detected both FGFRI and
FGFR2 mRNA in human kidneys, although the assays were not
isoform specific. Using in situ hybridization histochemistry, Jyo et
al [38] found none of the four FGFRs in rat glomeruli. In contrast
to studies with adult kidneys, all four FGFRs have been identified
in the developing kidney [39—43], although none of these studies
specifically addressed the localization of FGFR splice variants.
The aim of the present investigation was to determine whether
FGF-1 and FGF-2 and their high affinity receptors FGFR1,
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FGFR2, FGFR3 arid FGFR4 were expressed in normal rat
glomeruli. More specifically, because of the relevance to ligand
affinity and hence in vivo activation, we assessed the glomerular
expression of the FGFR IlIb and Ilic isoforms. RT-PCR was used
to detect mRNAs for these molecules in samples of whole cortex,
ten isolated glomeruli and single glomeruli. We have identified a
differential expression pattern for FGFRs between whole cortex
and glomeruli. In addition, we have identified a mutually exclusive
pattern of expression for FGFR1, 2 and 3 IlIb and IlIc isoforms
within glomeruli. Immunohistochemical studies using antisera
specific to the four FGFRs was also used to assess glomerular
expression of the FGFRs. The findings of this study have impor-
tant implications for the roles of the FGFs in the kidney.
Methods
Glomerular isolation
Adult female Sprague-Dawley rats were anesthetized with
sodium pentobarbitone (5 mg/I 00 g body wt; Nembutal, Abbott
Laboratories, Australia). Kidneys were cleared of blood with
Hanks' buffered salt solution by retrograde perfusion through the
abdominal aorta via a 21 gauge hypodermic needle at 180 mm Hg.
An incision in the inferior vena cava provided the outlet for the
perfusate. Once clear, kidneys were removed, decapsulated and
cut into 4 mm slices. The renal medulla was removed and cortical
pieces were either taken for analysis or consecutively passed
through 180 sm, 150 grm and 75 jsm sieves for isolation of
glomeruli. The glomerular-rich material retained on the top of the
Fig. 1. Design of RT-PCR assays for FGFs and
FGFRs, Double headed arrows below line
indicate the region of eDNA amplified in the
assay and its approximate size in base pairs.
Forward and reverse primers are indicated by
short horizontal arrows in right and left-hand
directions respectively. Thick downward-
pointing triangles indicate position of introns in
genes encoding the FGFs and FGFRs. The
assay is designed such that PCR products
generated from mRNA templates are distinct
from those of DNA templates. The FGFRs are
transmembrane receptors and the shaded
vertical line indicates the cell membrane. A
generic structure for an FGFR based on
FOFR1 is given here. The extracellular domain
has three Ig-like loops I, II and III. The N
terminal half of III is lila and this is joined to
a C terminal half, b or c, by alternative splicing
to generate the FGFR Ilib and TIle isoforms,
respectively. The Figure shows that for FGFR1
IlIb, for example, the forward primer is primer
1, the reverse primer is primer 3, and so on.
For FGFR assays two separate but closely
aligned regions of the receptor were targeted:
the Ig loop III and the transmembrane region.
finest sieve was then placed in petri dishes and individual glomer-
uli were selected by micropipetting with the aid of a dissecting
microscope and treated as described in RNA preparation below.
This entire procedure (from the start of the perfusion to place-
ment of samples in TRIzol) took approximately 15 minutes.
RNA preparation
Samples of whole cortex, ten glomeruli or single glomeruli were
pipetted into 0.8 ml of TRIzol reagent (Life Technologies, Gibco
BRL, Melbourne, Australia), vortexed vigorously to ensure com-
plete lysis, and then stored at —70°C until required. After the
samples were thawed 10 to 20 of glycogen (Boehringer
Mannheim, Melbourne, Australia) was added as carrier and the
samples then processed according to the manufacturer's instruc-
tions for small quantities of cells where total RNA was to be used
in RT-PCR. Isolated total RNA was then resuspended in 20 pl of
TE (10 mrvi Tris pH 8.0, 1 mtvi EDTA) and stored at —70°C.
Duplicate total RNA samples were prepared and analyzed from at
least three rats.
RT-PCR analysis of FGF and FGFR expression in glomeruli
Details of the design and methodology of the RT-PCR assays
used to detect the FGF mRNAs [44] and the FGFR mRNAs {5I
have been described previously. Diagrams of the PCR strategies
applied in all RT-PCR assays used in this study are given in Figure
1. Essentially, hot start PCR was employed using Ampliwax Gems
(Applied Biosystems, Melbourne, Australia) or "Hot Start" tubes
p2
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(Life Technologies, Gibco-BRL). The following PCR profiles
were used: 95°C one minute, 60°C one minute, and 72°C one
minute in OM1O Ratek water bath machine, or 95°C 30 seconds,
60°C 30 seconds and 72°C 30 seconds using a Corbett thermal
cycler (Proscience, Melbourne, Australia). The total number of
cycles used was 30 and the Mg2 optima was 2 m. The PCR
primers in these two studies were designed against mouse eDNA
sequences. While the rat and mouse sequences are very similar for
both the FGFs and the FGFRs, where species differences existed
in the eDNA sequences, new rat-specific primers were designed.
For FGF-2, the forward primer Ral (5' GCGACCCACACGT-
CAAACTACAGC) replaced the mouse-specific P1 from the
original assay [44, 451. All other FGF primers were identical to
those used in the mouse studies [44, 45].
For FGFR1 the forward primer rRl/1 (5' CTAGACGTFGT-
GGAGCGATCC; [42]) replaced mouse Ri/I [44, 45]. The inter-
nal primer rRl/5 (5' GTCCAGACAACYFGCCGTATGACC;
[42]) replaced the mouse RI/S for use as an internal probe in the
Southern detection of the PCR products from the FGFR1 assay.
All other FGFRI primers were as in the mouse studies.
For the FGFR2 IlIc isoform, the forward primer was R2/1 (5'
CCCATCCTCCAAGCTGGACTGCCT 3'), the reverse primer
was R2/4 (5' CTCCTTCTCTCTCACAGGTGCTGG; [46]) that
replaced mouse R2/4, and the internal oligonucleotide was R2/7
(5' GGTGTFAACACCACGGACAAAGAG), specific for exon
R2 Ilic and used for Southern detection of products produced by
R2/1 and R2/4. For the R2 Tub isoform, the reverse primer was
R2/3 (5 'ATCTGGGGAAGCCGTGATCTCCTT), and the inter-
nal oligonucleotide was R2/6 (5'CTGAAGCACTCGGGGATA-
AATAGC), which is specific for the exon R2 Ilib PCR product
and was used as the probe for Southern detection of PCR
products produced by R2/3 and R2/1.
For FGFR3, the mouse primers were used because the cDNA
sequence for the Ilib/Ilic region of the rat receptor is not
currently available. The rat and mouse receptors are highly
homologous in this region and it has been assumed that they will
be very similar.
For FGFR4, the primers were identical to those of the original
assay with the exception of the oligonucleotide rR4/7 (5'GAG-
GTGGAGGTGCTGTATCTGAGG; [47]), which was used as an
internal probe for Southern detection of the PCR products from
the FGFR4 assay.
For RT-PCR, 2 tl (1/10 of the total sample) of total RNA was
used for each FGF or FGFR isoform assay. The PCR conditions
and Southern analysis methodology were as previously described
[45]. In brief, for Southern blots exposure times varied from
necessity and were according to the amount of product present on
the gel. In general, times were of the order of 15 minutes for
cortex and samples from 10 glomeruli when products were visible
on a gel, and two to four hours for samples from single glomeruli
or samples not visible on a gel. Overnight exposures were used to
ensure that negative lanes were indeed negative. The negative
controls used were two primers alone (no eDNA), and these were
always negative (not shown in Figures). The design of the PCR
obviated the need for a minus RT control (Results and Discus-
sion). This permitted us to assay the two FGFs and up to seven
different receptor isoforms from within a single sample, including
samples of single glomeruli. Despite the considerable homology
between the various receptors, the design of the FGFR isoform
RT-PCR assay (namely the otigonucleotides, the conditions used
for the PCR and the Southern detection using an oligonucleotide
internal to the products) was such that there was discrimination in
the amplification of specific PCR products. Subcloning and se-
quence analysis of the PCR products produced verified the
Southern data.
Semiquantitative RT-PCR of gloinerular FGFR expression
This assay was conducted in a similar manner to the above
assays and was adapted from DeHamer et al [481 using primers
designed to the transmembrane region of the receptor (Fig. 1).
This is a region of least homology between the four receptors.
Consequently, all four receptors could be discriminated, and
additionally, both the Ilib and Ilic isoforms for each receptor
covered by the one assay. For FGFR1 the reverse primer (rp in
Fig. 1) sequence was 5' CGCGTGACCAAAGTGGCC 3', the
forward primer (fp in Fig. 1) AGAGACCAGCTGTGATGA, and
internal primer (ip in Fig. 1) AAGATGAAGAGCGGCACC. For
FGFR2 the reverse primer sequence was CGCCACGGTGACT-
GCCTC, the forward primer GAGAGAAGGAGATCACAG,
and internal primer CGAATGAAGACCACGACC. For FGFR3
the reverse primer sequence was GGCCACGGTGACAGGCTT,
the forward primer TGATGGAAACTGATGAGG, and internal
primer AGCTGTCATACTCTGCCG, and for FGFR4 the re-
verse primer was CAAACCAGCATCGTGGCT, forward primer
CGTGGACAACAGCAACAT and internal primer TGTAT-
CACCGACAAGTCA. Total RNA from cortex samples was used
to determine optimal PCR magnesium chloride concentration
and the appropriate cycle number that gave linear increments in
PCR amplification for each of the four FGFRs. Semiquantitative
RT-PCR was performed on duplicate samples of 10 glomeruli
from each of three rats. Southern blots were probed as described
previously using radiolabeled internal primers and relative signal
intensity determined using a Phospholmager (Fujix Bas 1000
Bio-Imaging Analyzer and MacBas Ver. 2.x.; Fuji Photo Film Co.
Ltd. and Kohshin Graphic Systems Inc., Tokyo, Japan).
Glomerular FGFR immunofluorescence
Kidneys from three rats were perfused clear of blood, as
described above, and then perfusion-fixed with 4% paraformalde-
hyde in phosphate buffered saline (PBS) pH 7.4 for five minutes.
Kidneys were dissected, decapsulated, cut into approximately 2
mm thick slices and placed into 5% sucrose in PBS for one hour
with constant agitation. Slices were then placed into 10% sucrose
in PBS for two hours, 30% sucrose in PBS for IS hours and into
1 part 30% sucrose in PBS to 1 part OCT compound (Tissue-Tek;
Miles, Elkhart, IN, USA) for 24 hours. Tissue slices were snap-
frozen in OCT compound and 5 1am sections cut on a cryostat and
collected onto 1% gelatinized slides. Sections were stored at
—20°C.
Glomerular FGFR localization was performed using indirect
fluorescent immunohistochemistry. Frozen sections were first
brought to room temperature and placed into PBS. All reactions
were performed in a humidified chamber at 22°C, except incuba-
tions with primary antibodies which took place at 4°C. Sections
were blocked with 10% normal goat serum (Sigma Chemical Co.,
St. Louis, MO, USA) with 0.5% Triton-X 100 (t-Octylphenoxy-
polyethoxyethanol; Sigma) in PBS for one hour. Sections were
then incubated with specific rabbit anti-FGFR antibodies (Santa
Cruz Biotechnology Inc.) at pre-determined optimal dilutions in
3% normal goat serum with 0.5% Triton-X 100 in PBS (diluent)
a a as
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Fig. 2. RT-PCR analysis of FGF-1 and FGF-2 expression in cortex and glomeruli. A. An ethidium bromide stained agarose gel photographed under UV
light after electrophoresis of PCR generated products. B. Southern analysis of the gel presented in the upper panel. Lanes 1 and 2, total RNA from
cortex; lanes 3 and 4, total RNA samples from 10 glomeruli (approximately 8,000 cells; [70]); and lanes 5 and 6, total RNA samples from single glomeruli(---800 cells). The results are representative of two replicate RT-PCR assays on two to four RNA preparations of individual samples from at least three
rats. Bands of the appropriate size for FGF-1 and FGF-2 mRNA are visible in all samples.
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Fig. 3. RT-PCR analysis of expression of FGFR Ilic isofbrms in cortex and glomendi. A. An ethidium bromide stained agarose gel photographed under
UV light after electrophoresis of PCR generated products. B. Southern analysis of the gel presented in A. Lanes 1 and 2, cortex total RNA; lanes 3 and
4, total RNA samples from 10 glomeruli; and lanes 5 and 6, total RNA samples from single glomeruli, the exception being FGFR3 Ilic where lanes 5
and 6 represent additional samples of 10 glomeruli. The results are representative of two replicate RT-PCR assays on two to four RNA preparations
of individual samples from at least three rats. The figure shows that all four Tile isoforms are expressed in whole cortex and glomeruli.
for 15 hours. The antibody concentrations were: FGFR1 (1:1000);
FGFR2 (1:500); FGFR3 (1:500); and FGFR4 (1:500). Control
sections were incubated with diluent alone or normal rabbit
serum. After three washes with PBS, sections were incubated with
Cy3-conjugated goat anti-rabbit IgG (Jackson ImmunoRcsearch
Laboratories, Inc., West Grove, PA, USA) at 1:1000 in diluent for
one hour, protected from light exposure. Sections were then again
washed with PBS and covcrslipped with Mowiol 4 to 88 (Hoechst
Aust. Ltd.) aqueous mountant.
Results
RT-PCR analysis of expression of FGF-1 and FGF-2 in cortex
and glomeruli
RT-PCR analysis of the expression of FGF-1 and FGF-2 is
shown in Figure 2. The expected product size for FGF-1 is 190
base pairs and for FGF-2 180 base pairs. Bands of the appropriate
size were clearly visible in RNA samples from cortex, ten glomer-
uli and single glomeruli. In each case the band visible on the gel
also hybridized with the internal probe specific for the product,
which verified that the product was derived from FGF mRNA.
The hands of higher molecular weight appearing in some of the
lanes (for example, lanes 1 and 2 for FGF-2) are non-specific
background PCR products that do not hybridize with the internal
probe. These results indicate that FGF-1 and FGF-2 are ex-
pressed in whole cortex and in glomeruli. Moreover, the mRNAs
are sufficiently abundant in single glomeruli to generate UV
visible products on a gel which hybridize strongly upon Southern
analysis.
RT-PcR analysis of expression of FGFR Ilic isoforms in cortex
and glomeruli
Results obtained for RT-PCR analysis of the expression of the
IlIc variant of all four FGFRs (FGFR1, FGFR2, FGFR3 and
FGFR4) are shown in Figures 3. The expected size of the Ilic
product is approximately 350 base pairs across all receptors. For
the FGFR1 assay, a product of this size was clearly visible in whole
cortex (Fig. 3, FGFR1, lanes 1 and 2) and within glomeruli (Fig.
3, FGFRI, lanes 3 and 4). Southern analysis showed that it was
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Fig. 4. RT-PCR analysis of expression of FGFR
IlIb isoforms in cortex and glomendi. A. An
ethidium bromide stained agarose gel
photographed under UV light after
electrophoresis of PCR generated products.
B. Southern analysis of the gel prcscnted in A.
Lanes 1 and 2, Cortex total RNA; lanes 3 and 4,
total RNA samples from 10 glomeruli. Thc
results are representative of two replicate RT-
PCR assays on two to four total RNA
preparations of individual samples from at least
three rats. The figure shows that FGFRI,
FGFR2 and FGFR3 Ilib isoforms are
expressed only in cortex.
also detectable within single glomeruli (Fig. 3B, FGFRI, lanes 5
and 6). For FGFR2 Ilic, a product was obtained in cortex and
glomeruli (Fig. 3). For FGFR3 IlIc, while a product was clearly
obtained for cortex, one was only occasionally detected in glomer-
uli. From a total of 20 glomerular samples tested, only six showed
expression.
The results obtained for FGFR4 showed two products in whole
cortex and isolated glomeruli, one at 350 base pairs and another
at approximately 480 base pairs (Fig. 3, FGFR4, lanes 1 and 2, and
lanes 3 and 4). Both products also hybridized to the FGFR4
specific oligonucleotide probe. The smaller of the two products
was generated from the FGFR4 mRNA while the larger was
derived from genomic DNA contamination of the RNA prepara-
tion, a common occurrence in total RNA preparations using
TRizol. FGFR4 genomic organization differs from the other
FGFR genes in that the exon encoding the N-terminal half of loop
III (exon a) and the C terminal half of the loop (exon c) are only
131 base pairs apart [49] as compared with approximately 2.4 kb
and 2.2 kb for FGFRI and FGFR2, respectively [14, 49, 50] and
1.6 kb for FGFR3 [17, 51]. These intron sizes for FGFR1, -2 and
-3 are sufficiently large that PCR products derived from contam-
inating DNA for these receptors are not produced under the PCR
conditions used here.
RT-PCR analysis of expression of FGFR IJIb isoforms in cortex
and glomeruli
Results obtained for RT-PCR analysis of expression of the Ilib
splice variants of FGFR1, FGFR2 and FGFR3 are shown in
Figure 4. For whole cortex, an FGFR1 Tub mRNA derived PCR
product of approximately 350 base pairs was not visible in the gel
(Fig. 4A, FUFRI, lanes 1 and 2), but was clearly visible upon
Southern analysis (Fig. 4B, FGFR1, lanes 1 and 2) using an
internal oligonucleotide probe for the FGFRI HIb product. In
contrast, there was no detectable product from glomerular RNA
(Fig. 4, FGFRI, lanes 3 and 4). Similarly, with regard to expres-
sion of the Tub variant of FGFR2, a 370 base pair product (the
Ilib product is larger than the Ilic product) was amplified from
cortical RNA but not from glomerular RNA (Fig. 4, FGFR2).
Also, for FGFR3 lIlh there was a product of expected size within
the cortex samples but none within glomerular samples (Fig. 4,
FGFR3).
Semiquantitative R T-PCR of glomerular FGFR expression
Semiquantitative analysis of FGFR expression within samples
of ten glomeruli revealed highest expression for FGFR1 (assigned
a value of 100%). The relative signal intensities for the other three
FGFRs were expressed as a percentage of the signal for FGFRI.
Values were: FGFR4 (6.2%), FGFR2 (0.1%), and FGFR3 (0%).
Glomerular FGFR immunofluorescence
Intense immunoreactivity was observed in glomeruli for
FGFR3 and FGFR4 (Fig. 5). Mild immunostaining was identified
for FGFR1 and a very low level of staining seen for FGFR2 (Fig.
5). For FGFR3 a mesangial immunostaining pattern was often
observed. However, the intensity of immunostaining for these
receptors varied widely within individual sections, and some
glomeruli showed no detectable immunostaining. The periphery
of glomerular capillary loops showed specific immunostaining for
FGFR4, suggesting specific immunostaining in glomerular epithe-
hal cells (podocytes). For FGFR1, some podocytes exhibited
specific immunostaining. The entire glomerulus appeared to
demonstrate specific immunostaining for FGFR2.
Discussion
The results reported here show that FGF-1 and FGF-2 as well
as several high affinity receptors for these growth factors are
expressed within normal rat glomeruli. These data are summa-
rized in Table 1. The results reveal differential expression of FGF
receptors in the kidney. We have shown that FGFR expression
differs between whole cortex and glomeruli: all seven receptor
isoforms were expressed in whole cortex, whereas only four
isoforms were expressed in glomeruli, the Ilic variants for each
receptor (FGFR1 to -4). There is thus a mutually exclusive
pattern of expression of FGFR isoforms within glomeruhi, with all
Ilic isoforms expressed, but no IlIb isoforms expressed. This
differential expression pattern, when considered together with the
relative affinities of the receptor isoforms for particular FGF
ligands, implies an exquisite in vivo regulation of the activity of
FGFs within glomeruhi.
Our results show that all four FGFRs are expressed in rat
kidney cortex, which is in agreement with other studies on
expression of these receptors in the rat, mouse and human kidney
[8, 9, 41—43]. We have extended these studies by localizing the
FGFR1
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Fig. 5. Fluorescence photographs of glomeruli imrnunostained forFGFRs. (A) FGFRI, (B) FGFR2, (C) FGFR3, (D) FGFR4, (E) control without primary
antibody, and (F) control with normal rabbit serum. Specific immunostaining is seen for all four FGFRs. A mesangial pattern of staining is seen for
FGFR3, while the periphery of capillary loops (presumably glomerular epithelial cells) is immunostained for FGFR4. The majority of the glomerulus
is immunostaincd for FGFR1 and FGFR2 (X500).
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Table 1. Comparison of FGF and FGFR isoform mRNA expression in
whole cortex and isolated glomeruli
FGF or FBFR Cortex Glomeruli
FGF-I + +
FGF-2 + +
FGFR1 11th + —
FGFR1 IlIc + +
FGFR2 Ilib + —
FGFR2IIIc + +
FGFR3 11th + —
FGFR3 Ilic + +1—
FGFR4 +
- ________
+
Abbreviations are: FGF, fibroblast growth factor; FGFR Ilib, fibroblast
growth factor receptor tub isoform; FGFR IIIc, fibroblast growth factor
receptor IlIc isoform. Note that FGFR1, -2 and -3 have IlIb and IIIc
isoforms, while FGFR4, because it lacks a "b" exon in its genomic
structure 1491, has just a "tile-like" isoform and is simply referred to as
FGFR4. Data are representative of two replicates from each of two to four
tissue samples from three rats.
expression of particular isoforms of FGFR1, FGFR2 and FGFR3
to glomeruli. Significantly, our results reveal a mutual exclusivity
of expression of FGFR1 to -3 Tub and Ilic isoforms in the
glomerulus. This manner of expression of the Ilib and Ilic splice
variants has been described in several previous studies [17, 46, 501.
It is particularly interesting and noteworthy to find this kind of
expression pattern in a structure such as the glomerulus. These
findings indicate that FGFR isoform expression, and thereby FGF
activity, are tightly regulated within glomeruli.
The relevance of FGFR isoform expression to FGF activation is
emphasized by findings from recent studies on embryonic devel-
opment and prostate cancer. These studies have revealed that
differential expression of the FGFRs occurs throughout develop-
ment in a range of tissues. These data suggest that specific and
discrete expression of FGFR1 and FGFR2 acts to regulate the
activity of the FGFs being expressed in a spatial and temporal
manner [39, 40]. It has also been shown that the two FGFR2
isoforms, FGFR2 tub and FGFR2 lIle, are differentially localized
during development [52]. Yan et a! [46] reported the dramatic
consequences of an abnormal switch in isoform expression in
studies on FGFR2 expression in prostate cancer. A change from
the exclusive expression of the FGFR2 Ilib isoform to the
exclusive expression of the FGFR2 IlIc isoform occurred concur-
rently with the progression to malignancy. Because of the differ-
ential specificity of these two isoforms for FGF ligands, it would
appear that the switch in expression subverts the normal regula-
tion of growth by activating the effects of other FGFs such as
FGF-2.
The differential renal expression pattern of FGFR isoforms
becomes more interesting when one considers the relative affini-
ties of particular FGFs for these isoforms (summarized in Table
2). It is clearly apparent that FGFs will specifically select one
isoform over another [10, 53—56]. These binding affinities together
with the present data on receptor expression indicate that three
isoforms with a high affinity for FGF-1, namely FGFR1 tIle,
FGFR2 he and FGFR3 tile, are present in glomeruli and could
potentially mediate the effects of FGF-1. With regard to FGF-2,
there are fewer high affinity receptors available within glomeruli,
as FGFR2 and R3 IlIc isoforms have lower affinities for FGF-2
than FGFR1I1Ic, which binds FGF-2 with equal affinity to FGF-1.
FR2c, FR1c, FR3b, FR3c
FR1b, FR1c, FR2b, FR3b
FR1b, FR2b
This table lists the documented binding preferences of particular FGFs
for specific FGFR (FR) isoforms. This list is not complete as data on
specific isoform preferences are not available for some FGFs. The
references from which the material for the table has been compiled are
given in the text. The selection of one isoform of a particular receptor over
another by those FGFs for which the tub versus lIle affinity has been well
documented is quite dramatic and clearly obvious from this compilation.
FGF-2 and FGF-1 could also potentially be bound by FGFR4,
which is also expressed in glomeruli. However, there is some
controversy about the binding affinity of FGFR4, with one report
[9] indicating only FGF-1 was bound, while another [57] indicated
that FGFR4 binds both FGF-1 and FGF-2 with the highest affinity
for FGF-1.
The RT-PCR assay used in the present study does not indicate
whether the PCR products were derived from a full-length
receptor (the 3-ioop form or a variant). However, other studies on
receptor expression in the kidney do suggest that full-length
receptors are present. Two PCR studies on expression of FGFRI
variants in kidney [42, 58], have shown that the full length
receptor (a variant) and a 2 loop form (f3 variant) are highly
expressed, with the f3 variant being more abundant during devel-
opment [41]. Other studies employing Northern analysis indicate
that the mRNAs for FGFR2, -3 and -4 are of an appropriate size
to encode full-length potentially functional receptors [8, 9, 47, 59].
The results obtained for FGFR3 mRNA would appear to
indicate a variable and low level expression in glomeruli. These
results are compatible with the protein localization data for
FGFR3 that revealed marked staining in some, but not all
glomeruli. The semiquantitative RT-PCR assay directed towards
detecting the transmembrane region of the FGFRs did not detect
a product for FGFR3, whereas the RT-PCR assay directed
towards loop III did show it. This could result from a combination
of factors including the relative efficiencies of the two assays.
Specifically, the variable and low level quality of FGFR3 expres-
sion in glomeruli may have been below the threshold of detection
for the less efficient assay. It is also possible, given the huge array
of FGFR variants that exist, that an FGFR3 variant that has
deleted a large section of the receptor containing the transmem-
brane domain occurs within glomeruli. Such a variant has been
previously described in a breast epithelial cell line [60]. The
antibodies used in the present study are directed against the
COOH terminal portion of the receptors and would therefore
detect such a variant. The results from the immunofluorescence
studies also suggest that the glomerular levels of FGFR1 protein
are relatively low, despite its mRNA expression being the highest
FGFs
Table 2. FGFR isoform preferences of the family of FGF ligands
FGFR isoform
binding
FGFR isoform
non-binding
FGF-I
FGF-2
FGF-3
FGF-4
FGF-5
FGF-6
FGF-7
FGF-8
FGF-9
all isoforms
FRIc> FR1b > FR2c,
FR3, FR4
FRIb, FR2b >> FR2c
FRIc, FR2c, FR4
FRI
? ?
FR2b>> FR1b
FR3c> FR2c, FR4
FR3c> FR2c, FR4>
FR3b > FRIc
none
FR2b
FR1c, FR3b, FR3c and FR4
FR3
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of all three receptors present in glomeruli. In contrast, the level of
FGFR4 protein appears to be quite high despite the fact that the
mRNA expression level was one-tenth that of FGFRI. Antibody
affinity and relative levels of translation efficiency and protein
stability aside, this may be due in part to uniformity of expression.
FGFR1 protein, while apparently low in amount, was present in
all glomerular profiles (the 2-dimensional samples of glomeruli
seen in sections) examined while FGFR4 was not.
In contrast to the present results, Floege et al [34] were unable
to detect bFGF-receptor immunofluorescence in normal rats.
Floege et al [341 used an antibody raised against a peptide that
corresponded to the external region of the fig receptor (FGFR1).
These differing results may reflect the differences between anti-
bodies, or alternatively, may indicate expression of particular
FGFRI isoforms.
Jyo et al [38] were unable to demonstrate mRNA for any of the
FGFRs in normal rat glomeruli using in situ hybridization histo-
chemistiy. A mesangial pattern of mRNA expression was ob-
served in rats with mesangial proliferative nephritis. The differ-
ence between the present findings and those of Jyo et a! [38] most
likely reflects the greater sensitivity of RT-PCR compared with in
situ hybridization histochemistry. While not within the scope of
the present study, the technique of in situ PCR, which has both
sensitivity and localization, may be the most appropriate approach
for future studies.
The present finding of differential expression of FGFR isoforms
suggests that glomeruli can regulate FGF activity through selec-
tive expression of specific receptor isoforms. It also implies the
potential importance of other FGFs whose expression has not
been evaluated in this study.
It is also essential to keep in mind that the FGFs and the
FGFRs rely on interactions with a low affinity class of receptor,
namely the heparan sulfate proteoglycans, for intracellular signal-
ing. It is becoming apparent that highly sulfated domains within
the heparan sulfate sidechains have specificity for particular FGFs
[61—63]. Additionally, and perhaps more critical to these kinds of
discussion on FGF activation are the implications from recent
studies on heparan sulfates, which show that at specific times
during development cells are able to synthesize heparan sulfates
that are not only capable of specifically binding an FGF, but also
of selecting a particular FGFR for signal transduction [44, 45].
The potentially enormous variety of specific and receptor-selec-
tive heparan sulfates that could be synthesized in the glomerulus
adds yet another subtle level of diversity to the range of responses
available to an FGF ligand in vivo.
Although the present data on FGF and FGFR expression
within glomeruli adds to our understanding of potential FGF
activity within glomeruli, much is yet to be learned about the
biological activities of these molecules in developing, normal and
diseased glomeruli. Presumably, as in other tissues, the FGFs play
a role in the regulation of glomerular cell proliferation and
differentiation, and extracellular matrix. FGF-2 has been shown to
be mitogenic for cultured mesangial cells [23, 64], glomerular
endothelial cells [65] and podocytes [24]. There have been several
reports of the effects of FGF-2 administration on glomerular
structure and function. Administration of FGF-2 to monkeys
resulted in proteinuria, hyperplasia of the parietal epithelium and
podocyte foot process effacement [66]. Administration of FGF-2
to rats resulted in proteinuria, podocyte enlargement and vacuo-
lation as well as foot process effacement. Kriz et al [67] recently
reported that long-term FGF-2 administration to rats resulted in
focal segmental glomerulosclerosis. Changes to podocytes were
observed, including mitotic figures, binucleate and multinucleate
cell bodies, cell body attenuation, pseudocyst formation, foot
process effacement and detachment from the glomerular base-
ment membrane. Floege et al [681 reported that administration of
FGF-2 induced proliferation of mesangial cells in anti-Thy 1.1 rats
but was ineffective in normal rats. Floege et al [34] subsequently
showed that FGF-2 augments podocyte injury and glomeruloscle-
rosis in rats with membranous nephropathy. There have also been
reports of altered levels of FGF-2 mRNA in diseased glomeruli.
For example, Nakamura et al [69] reported that glomerular levels
of FGF-2 mRNA increased with the progression of glomerular
sclerosis in unilaterally nephrectomized rats administered puro-
mycin aminonucleoside. Taken together, these studies provide the
first evidence for a variety of roles for FGF-2 in normal and
diseased glomeruli.
In summary, we have used RT-PCR and immunohistochemistry
to analyse the expression pattern of FGF-1, FGF-2 and seven
FGFR isoforms in the rat kidney. We have identified a differential
expression pattern of the FGFR isoforms between whole cortex
and glomeruli, as well as a mutually exclusive pattern of FGFR
isoform expression within glomeruli. As these receptor isoforms
bind the FGFs with differing affinities, these data have important
implications for the roles of the FGFs in normal and diseased
glomeruli.
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